D.E. Shaw & Co
VERV

D.E. Shaw & Co’s Verve Therapeutics VERV Stock Holding History

D.E. Shaw & Co’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-10,586
Closed -$119K – 4952
2025
Q2 		$119K Sell
10,586
-46,518
-81% -$265K ﹤0.01% 4114
2025
Q1 		$261K Buy
57,104
+19,120
+50% +$128K ﹤0.01% 3828
2024
Q4 		$214K Buy
+37,984
New +$214K ﹤0.01% 4055
2024
Q2 		– Sell
-310,205
Closed -$4.12M – 4869
2024
Q1 		$4.12M Buy
310,205
+88,158
+40% +$1.17M ﹤0.01% 2032
2023
Q4 		$3.1M Buy
+222,047
New +$2.75M ﹤0.01% 2312
2022
Q4 		– Sell
-7,062
Closed -$243K – 5148
2022
Q3 		$243K Sell
7,062
-87,063
-92% -$2.78M ﹤0.01% 4392
2022
Q2 		$1.44M Buy
94,125
+3,119
+3% +$48.3K ﹤0.01% 3360
2022
Q1 		$2.08M Buy
91,006
+78,380
+621% +$2.24M ﹤0.01% 3255
2021
Q4 		$466K Sell
12,626
-88,840
-88% -$3.73M ﹤0.01% 4444
2021
Q3 		$4.77M Buy
101,466
+43,647
+75% +$2.57M ﹤0.01% 2142
2021
Q2 		$3.48M Buy
+57,819
New +$2.4M ﹤0.01% 2361

Other funds holding VERV

GCM
Greenland Capital Management New York $787M AUM 40.68% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
BIG
Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

D.E. Shaw & Co's VERV Position: Q3 2025 in Review

D.E. Shaw & Co sold out of Verve Therapeutics (VERV) in Q3 2025, closing a stake of 10,586 shares — an estimated $119K sold.

D.E. Shaw & Co first reported a position in VERV in Q2 2021 and held it in 11 quarters. The position peaked at $4.77M in Q3 2021. 6 funds tracked by Wall St. Rank hold VERV as of Q3 2025.

  • D.E. Shaw & Co reported no remaining Verve Therapeutics position as of Q3 2025 after selling out during the quarter.
  • D.E. Shaw & Co sold 10,586 Verve Therapeutics shares in Q3 2025, an estimated $119K.
  • D.E. Shaw & Co first reported a position in Verve Therapeutics in Q2 2021 and held it in 11 quarters.
  • D.E. Shaw & Co's Verve Therapeutics position peaked at $4.77M in Q3 2021.
  • 6 funds tracked by Wall St. Rank held Verve Therapeutics as of Q3 2025.

Based on D.E. Shaw & Co's 13F filing for Q3 2025, filed 14 Nov 2025.